The Norwegian island of Klosterøy is famous for its medieval monastery, but new research suggests it was important long before that. When you purchase through links on our site, we may earn an ...
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...
River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...
Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have ...
Hosted on MSN
Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts
Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback